Almost everyone asking about weight loss medication in Dubai arrives with a brand name rather than a question. Ozempic, Wegovy, Mounjaro — the names travel faster than the facts, and by the time someone reaches a consultation they have usually heard a dramatic story from a friend and read something alarming online.
This article explains what these medicines are, what the large published trials measured, and what the evidence does not tell us. It does not tell you whether one is right for you. That is a decision for a doctor who has seen your history, your bloods and your medication list — these are prescription-only medicines with real eligibility criteria and real side effects, and they are not dispensed on request.
Three brands, two molecules
The first thing worth untangling is that the brand names describe fewer drugs than people assume. Ozempic and Wegovy are the same molecule, semaglutide, licensed at different doses for different purposes — Ozempic for type 2 diabetes, Wegovy at a higher dose for weight management. Mounjaro is a different molecule, tirzepatide.
The distinction that matters clinically is how they work. Semaglutide is a GLP-1 receptor agonist: it mimics a gut hormone released after eating, which slows stomach emptying and reduces appetite. Tirzepatide does the same thing but also acts on a second receptor, GIP. Whether that dual action explains the difference in trial results is still being argued over; that it produces a difference is not.
- Semaglutide — sold as Ozempic (type 2 diabetes) and Wegovy (weight management)
- Tirzepatide — sold as Mounjaro, acting on both GLP-1 and GIP receptors
- Liraglutide — an older, daily GLP-1 medicine, largely superseded by the weekly options
- Oral semaglutide — a tablet form, sold as Rybelsus for type 2 diabetes
What the trials found
The headline figures come from two large randomised trials, both published in the New England Journal of Medicine.
STEP 1 studied semaglutide 2.4 mg in 1,961 adults with overweight or obesity, alongside lifestyle intervention. At 68 weeks, mean weight change was −14.9% with semaglutide against −2.4% with placebo, and 86% of those on treatment lost at least 5% of their body weight.
SURMOUNT-1 studied tirzepatide in adults with obesity or overweight. At 72 weeks, average reductions were 16.0%, 21.4% and 22.5% on the 5 mg, 10 mg and 15 mg doses respectively, against 2.4% for placebo.
Those are averages across thousands of people, not a forecast for any individual. The trials also included structured lifestyle support throughout — diet and activity counselling was part of both arms, not an optional extra. Nobody in these studies took a medicine and changed nothing else.
The cardiovascular finding people miss
The most consequential result is not about weight at all. The SELECT trial randomised 17,604 adults who had overweight or obesity and established cardiovascular disease but not diabetes, and followed them for around three years.
Major adverse cardiovascular events — cardiovascular death, non-fatal heart attack or non-fatal stroke — occurred in 6.5% of those on semaglutide against 8.0% on placebo, a hazard ratio of 0.80. In other words, roughly a 20% relative reduction in a group already at high risk.
This matters because it reframes what the medicine is for. In that population it was doing something beyond changing a number on a scale. It also does not generalise to everybody: the participants all had existing cardiovascular disease, which most people asking about these medicines do not.
Side effects and who should not take them
The common side effects are gastrointestinal and dose-related: nausea, vomiting, diarrhoea, constipation. They are most pronounced when the dose is increased, which is why prescribing starts low and titrates slowly with review at each step. For most people who continue, they settle.
Rarer but more serious concerns include pancreatitis, gallbladder disease and, in people already at risk, dehydration affecting kidney function. There are absolute contraindications — a personal or family history of medullary thyroid carcinoma or MEN2 syndrome among them — and interactions with other medicines that a prescriber has to check.
This is the part that gets lost when a medicine becomes fashionable. These are not lifestyle products. They are prescription medicines that require assessment before starting, monitoring during, and a plan for stopping.
What a proper assessment looks like
Weight is a symptom before it is a diagnosis. A consultation that jumps straight to a prescription has skipped the part that decides whether the prescription is even the right answer — thyroid function, insulin resistance, other medications that cause weight gain, sleep, and mental health all change the plan.
At Smart Care Polyclinic that means a doctor consultation, measurements and blood tests before anything is prescribed, and follow-up appointments that track more than the scale. Where medication is clinically appropriate, it is one part of a plan rather than the whole of it.
Common questions
Is Ozempic the same as Wegovy?
They contain the same molecule, semaglutide, but are licensed at different doses for different purposes — Ozempic for type 2 diabetes and Wegovy at a higher dose for weight management. They are not interchangeable, and which is appropriate is a prescribing decision.
Is Mounjaro better than Ozempic for weight loss?
In their respective trials tirzepatide produced larger average weight reductions than semaglutide, but the studies were designed and run separately, in different populations, so comparing headline numbers across them is not the same as a head-to-head result. Which is more suitable depends on your medical history, not on which number is bigger.
Can I get a GLP-1 prescription without a consultation?
No. These are prescription-only medicines with eligibility criteria, contraindications and required monitoring. A DHA-licensed doctor must assess you first, and part of that assessment is deciding whether medication is appropriate at all.
Do I have to take it forever?
That is the honest and unresolved question, and it is covered in detail in our companion article on what happens when you stop. The trial evidence shows most of the lost weight returns after withdrawal, which is why any responsible plan discusses maintenance before it starts.
References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221-2232.
This article is general health information, not medical advice, and does not replace a consultation. Care at Smart Care Polyclinic is provided by DHA-licensed clinicians.